Advances in pre-clinical cancer models
Guest Edited by Ryan C. Fields and Anna Golebiewska
Extracellular vesicles in cancer progression
Guest Edited by: Orazio Fortunato, Irina Matei and Chunlin Ou
Advances in pre-clinical cancer models
Guest Edited by Ryan C. Fields and Anna Golebiewska
Extracellular vesicles in cancer progression
Guest Edited by: Orazio Fortunato, Irina Matei and Chunlin Ou
Click here to view which Articles have been shared most in the last month!
Targeted Therapies for Cancer
Guest edited by Prof. Min Li and Dr. Yanis Boumber
Open for submissions
Microbiome and Cancer
Guest edited by Christopher Staley, Jacques Ravel, Sean Devlin
Open for submissions
Cross journal collection: Advances in CAR-T immunotherapy
Guest edited by Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
Collection published: 30 June 2020
Cross journal collection: Precision Oncology
Collection published: 28 August 2019
Browse all BMC Cancer collection contributions
MULISARC trial: molecular profiling of advanced soft-tissue sarcomas
THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy
Learn more about study protocols at BMC Cancer here
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here.
On occasion of the Esophageal Cancer Awareness Month we hope you will enjoy reading the following article published in BMC Cancer in 2022 suggesting that CTCs in patients during follow-up after tri-modality therapy are associated with significantly poorer DFS and OS regardless of timing of chemoradiotherapy.
Interested in joining the editorial board of BMC Cancer?
More information and how to apply can be found here. We are looking forward to hearing from you.
BMC Cancer is celebrating its 20th anniversary!
Since launching in 2001, we've become established as the largest open access oncology journal in our field. We're proud of our history of making cancer research and methods available to all. We have been looking back at our achievements and highlighted some of the most influential research published in the journal over the past two decades.
27 January 2023
16 January 2023
Your browser needs to have JavaScript enabled to view this timeline
Citation Impact
4.638 - 2-year Impact Factor (2021)
4.672 - 5-year Impact Factor (2021)
1.308 - SNIP (Source Normalized Impact per Paper)
1.134 - SJR SCImago Journal Rank (SJR)
Speed
37 days to first decision for all manuscripts (Median)
65 days to first decision for reviewed manuscripts only (Median)
Usage
6,897,358 Downloads (2021)
4,517 Altmetric mentions (2021)
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication